Pages
Products
Rituximab Stable Cell Line - CHO-K1

Rituximab Stable Cell Line - CHO-K1

Cat.No. :  CSC-BS0001 Host Cell:  CHO-K1

Inquire for Price

Cell Line Information

Safety and Packaging

Cat. No. CSC-BS0001
Description This cell line is engineered to stably produce Rituximab which is a monoclonal antibody against human MS4A1/CD20.
Biosimilar Rituximab
Host Cell CHO-K1
Host Cell Species Cricetulus griseus (Chinese hamster)
Stability Validated for at least 10 passages
Application

1. Biosimilar Development

2. Large-Scale Biomanufacturing

3. Preclinical Research

4. Drug Development and Testing

Growth Conditions 37° C, 5% CO2
Quality Control Negative for bacteria, yeast, fungi and mycoplasma.
Shipping Dry ice
Storage Liquid nitrogen
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Publications

Q & A

Customer Reviews

Customer Q&As
What is Rituximab?

A: Rituximab is a monoclonal antibody commonly used to treat various types of cancer and autoimmune diseases.

What is the mechanism of action of Rituximab?

A: Rituximab works by binding to the CD20 protein on the surface of cancerous B cells. This binding sets off a chain of events that culminates in the destruction of these cancer cells through a process called antibody-dependent cellular cytotoxicity (ADCC).

What is rituximab treatment for?

A: Rituximab injection is used alone or with other medicines to treat a type of cancer called non-Hodgkin's lymphoma (NHL). It is also used in combination with other anticancer drugs to treat mature B-cell non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-AL).

What is the success rate of rituximab?

A: Rituximab, used as a single agent, is very effective in several types of indolent lymphoma, with response rates (RR) of 45% to 60% even in treated patients,1-3 and in more In the aggressive form of NHL, the response rate (RR) is approximately 30%.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Maintain consistency across batches

These Rituximab Stable Cell Lines are capable of growing under very specific conditions, which can be easily replicated to maintain consistency across batches.

United States

08/23/2020

Ideal platform for commercial production

The CHO-K1 cells can produce high levels of rituximab, making it an ideal platform for commercial production.

United States

05/12/2021

Effective

Great buy! The Rituximab Stable Cell Line remains effective in targeting the CD20 protein across multiple generations.

United States

08/15/2021

Can large-scale production of rituximab

The use of these cell lines has allowed for the large-scale production of rituximab. I recommend it.

Germany

10/09/2021

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction